Advertisement

Topics

"A Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment (PVD)" Drugs and Medication Database

09:25 EST 18th February 2019 | BioPortfolio

Here are the most relevant "A Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment (PVD)" Drugs and Medications that we have found in our database.

More Information about "A Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment (PVD)" on BioPortfolio

We have published hundreds of A Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment (PVD) news stories on BioPortfolio along with dozens of A Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment (PVD) Clinical Trials and PubMed Articles about A Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment (PVD) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of A Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment (PVD) Companies in our database. You can also find out about relevant A Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment (PVD) Drugs and Medications on this site too.

Showing "Study Evaluate Plasmin Creation Posterior Vitreous Detachment" Drugs and Medications 1–25 of 47

Probably Relevant

Jetrea [thrombogenics inc.]

These highlights do not include all the information needed to use JETREA safely and effectively. See full prescribing information for JETREA JETREA (ocriplasmin) injection, for intravitreal injectionInitial U.S. Approval: 2012

Retisert [bausch & lomb incorporated]

These highlights do not include all the information needed to use RETISERT safely and effectively. See full prescribing information for RETISERT. RETISERT (fluocinolone acetonide intravitreal implant) 0.59 mg for intravitreal use Initial U.S. Approval: 19

Membraneblue [dutch ophthalmic research center (international) b.v.]

MembraneBlue™ 0.15% (trypan blue ophthalmic solution). These highlights do not include all the information needed to use MembraneBlue™ 0.15% safely and effectively. See full prescribing information for MembraneBlue™ 0.15%. MembraneBlue™ 0.15% (try

Possibly Relevant

Ozurdex [allergan, inc.]

These highlights do not include all the information needed to use OZURDEX® safely and effectively. See full prescribing information for OZURDEX . OZURDEX (dexamethasone intravitreal implant) For Intravitreal Injection Initial U.S. Approval: 1958

Visionblue [d.o.r.c. dutch ophthalmic research center (international) b.v.]

VisionBlue® 0.06% Trypan blue Ophthalmic Solution. These highlights do not include all the information needed to use VISIONBLUE® 0.06% safely and effectively. see full prescribing information for VISIONBLUE® 0.06%. VisionBlue® (trypan blue ophthalmic

Yutiq [eyepoint pharmaceuticals us, inc]

These highlights do not include all the information needed to use YUTIQ safely and effectively. See full prescribing information for YUTIQ.YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg, for intravitreal injectionInitial U.S. Approval: 1963

Dexycu [eyepoint pharmaceuticals us, inc]

These highlights do not include all the information needed to use DEXYCU™ safely and effectively. See full prescribing information for DEXYCU. DEXYCU (dexamethasone intraocular suspension) 9%, for intraocular administrationInitial U.S. Approval: 1958

Phocal apf [u.s.i.a. inc]

phocal™

Iluvien [alimera sciences, inc.]

These highlights do not include all the information needed to use ILUVIEN® safely and effectively. See full prescribing information for ILUVIEN. ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg For Intravitreal Injection Initial U.S. Appro

Brimonidine tartrate [physicians total care, inc.]

NA

Brimonidine tartrate [sandoz inc]

These highlights do not include all the information needed to use Brimonidine Tartrate Ophthalmic Solution, 0.15% safely and effectively. See full prescribing information for Brimonidine Tartrate Ophthalmic Solution, 0.15%. Brimonidine Tartrate Ophthalmic

Phocal phn [phocal therapy inc]

phocal™

Ganciclovir [exela pharma sciences, llc]

These highlights do not include all the information needed to use GANCICLOVIR INJECTION safely and effectively. See full prescribing information for GANCICLOVIR INJECTION. GANCICLOVIR INJECTION, for intravenous useInitial U.S. Approval: 1989 

Alphagan p [physicians total care, inc.]

These highlights do not include all the information needed to use ALPHAGAN P safely and effectively. See full prescribing information for ALPHAGAN P. ALPHAGAN P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15% Initial U.S. Approval: 1996

Alphagan p [allergan, inc.]

These highlights do not include all the information needed to use ALPHAGAN P safely and effectively. See full prescribing information for ALPHAGAN P.     ALPHAGAN P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15% Initial U.S. Approval: 1996

Latanoprost [rebel distributors corp]

Latanoprost Ophthalmic Solution 0.005% (50 ug/mL)

Xalatan [dispensing solutions, inc.]

Xalatan latanoprost ophthalmic solution0.005% (50 µg/mL)

Lucentis [genentech, inc.]

These highlights do not include all the information needed to use LUCENTIS safely and effectively. See full prescribing information for LUCENTIS. LUCENTIS (ranibizumab injection) for intravitreal injection Initial U.S. Approval: 2006

Latanoprost [physicians total care, inc.]

Latanoprost Ophthalmic Solution 0.005% (50 ug/mL)

Latanoprost [direct rx]

LATANOPROST

Eylea [regeneron pharmaceuticals, inc.]

These highlights do not include all the information needed to use EYLEA safely and effectively. See full prescribing information for EYLEA. EYLEA (aflibercept) Injection, for Intravitreal InjectionInitial U.S. Approval: 2011

Mitosol [mobius therapeutics llc]

These highlights do not include all the information needed to use Mitosol safely and effectively. See full prescribing information for Mitosol. Mitosol (mitomycin for solution) for ophthalmic useInitial U.S. Approval: 1974

Ganciclovir [sagent pharmaceuticals]

These highlights do not include all the information needed to use GANCICLOVIR INJECTION safely and effectively. See full prescribing information for GANCICLOVIR INJECTION. GANCICLOVIR injection, for intravenous useInitial U.S. Approval: 1989

Ganciclovir [par pharmaceutical, inc.]

These highlights do not include all the information needed to use GANCICLOVIR FOR INJECTION safely and effectively. See full prescribing information for GANCICLOVIR FOR INJECTION. Ganciclovir for injection, for intravenous useInitial U.S. Approval: 1989

Cytovene [genentech, inc.]

These highlights do not include all the information needed to use CYTOVENE-IV safely and effectively. See full prescribing information for CYTOVENE-IV. CYTOVENE-IV (ganciclovir sodium) for injection, for intravenous use Initial U.S. Approval: 1989



Advertisement
Quick Search
Advertisement
Advertisement